http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
ASimple Online Identification Method Using Sliding Mode Technique
Shinichiro Nakagawa,EikoFurutani 제어로봇시스템학회 2009 제어로봇시스템학회 국제학술대회 논문집 Vol.2009 No.8
In this paper, a simple online identification method for single-input single-output systems utilizing the idea of sliding mode control is proposed. The method uses a simplified model with an adjustable parameter of the plant, adjusts the parameter so that the error between outputs of the plant and the model for a step input convergesto zero, and gives an identification result as the adjusted parameter. Through a single identification procedure one parameter of the plant can be obtained. The simulation result shows that the method is useful for parameter identification of plants.
Kuwamoto, Kana,Takeda, Yuri,Shirai, Akiko,Nakagawa, Tsutomu,Takeishi, Shunsaku,Ihara, Shinji,Miyamoto, Yasuhide,Shinzaki, Shinichiro,Ko, Jeong Heon,Miyoshi, Eiji D. A. Spandidos 2010 MOLECULAR MEDICINE REPORTS Vol.3 No.4
<P>α2-Heremans-Schmid glycoprotein (human fetuin) is one of numerous serum proteins produced in the liver. Recently, the biological functions of fetuin, such as calcification and insulin resistance, have been clarified. However, these effects appear to be indirect, occurring through binding to other molecules. When equal amounts of fetuin in sera were treated with chymotrypsin, resistance to the protease treatment was observed in patients with pancreatic cancer, but not in normal volunteers. To investigate the molecular mechanism behind this resistance, gel-filtration chromatography was performed. The results revealed that high molecular types of fetuin showed a resistance to protease treatment. When fetuin was purified from sera of patients with pancreatic cancer and normal volunteers, certain types of proteins, including haptoglobin (which binds to fetuin derived from pancreatic cancer patients), were identified using mass spectrometry. Furthermore, the oligosaccharide structures of fetuin analyzed with lectin microarray differed between pancreatic cancer patients and normal volunteers. This macro/micro heterogeneity of fetuin might contribute to pancreatic cancer resistance to chymotrypsin treatment.</P>
Yoshinori Sakurai,Hiroki Tanaka,Takushi Takata,Nozomi Fujimoto,Minoru Suzuki,Shinichiro Masunaga,Yuko Kinashi,Natsuko Kondo,Masaru Narabayashi,Yosuke Nakagawa,Tsubasa Watanabe,Koji Ono,Akira Maruhashi 한국물리학회 2015 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.67 No.1
At the Kyoto University Research Reactor Institute (KURRI), a clinical study of boron neutron capture therapy (BNCT) using a neutron irradiation facility installed at the research nuclear reactor has been regularly performed since February 1990. As of November 2014, 510 clinical irradiations were carried out using the reactor-based system. The world’s first accelerator-based neutron irradiation system for BNCT clinical irradiation was completed at this institute in early 2009, and the clinical trial using this system was started in 2012. A shift of BCNT from special particle therapy to a general one is now in progress. To promote and support this shift, improvements to the irradiation system, as well as its preparation, and improvements in the physical engineering and the medical physics processes, such as dosimetry systems and quality assurance programs, must be considered. The recent advances in BNCT at KURRI are reported here with a focus on physical engineering and medical physics topics.